Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Quantum Genomics (QNNTF : OTC)
 
 • Company Description   
Quantum Genomics is a biopharmaceutical company. It specialises in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of cerebral Aminopeptidase A. Quantum Genomics is based in France.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.40 Daily Weekly Monthly
20 Day Moving Average: 0 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta:
52 Week High: $4.50
52 Week Low: $3.40
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.00% 12.62%
12 Week -24.44% -16.94%
Year To Date -24.44% -7.68%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
33 Rue Marbeuf
-
Paris,I0 75008
FRA
ph: 33-01-85-34-77-70
fax: -
None http://www.quantum-genomics.com
 
 • General Corporate Information   
Officers
Jean Philippe Milon - Chief Executive Officer
Lionel Segard - Chairman
Mark Karako - Chief Financial Officer
Fabrice Balavoine - Director
Bruno Besse - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: F76288111
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.20 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©